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Background: The aim of this study was to determine the recommended dose of irinotecan
(CPT-11) with ﬁxed regimen of oxaliplatin (L-OHP)/ﬂuorouracil (5-FU)/leucovorin (LV) (FOL-
FOXIRI) plus bevacizumab in Japanese patients with metastatic colorectal cancer.
Patients and methods: Patients received CPT-11 followed by L-OHP 85 mg/m2, LV 200 mg/m2,
and 5-FU 3200 mg/m2 infused as a 48-h continuous infusion and bevacizumab 5 mg/kg, repeated
every 2 weeks. A decrease of the CPT-11 dose was planned (started at level 1: CPT-11 165 mg/
m2). This trial was registered with the University Hospital Medical Information Network (number
UMIN000012991).
Results: Six patients were enrolled, and MTD was not reached at level 1. CPT-11 165 mg/ in
combination with L-OHP 85 mg/m2, LV 200 mg/m2, 5-FU 3200 mg/m2 infused as a 48-h
continuous infusion and bevacizumab 5 mg/kg could be administered with acceptable toxicity,
and all patients were treated at these dose levels. The most common grade 3 or 4 toxicities
were neutropenia (67%) and leukopenia (50%). No treatment death was observed. The overall
response rate was 67% (95% conﬁdence interval: 30.0–90.3 %).
Conclusion: This biweekly triplet plus bevacizumab regimen was well tolerated by Japanese
patients with metastatic colorectal cancer. The recommended phase II dose was determined to
be the same as the standard doses for this regimen used worldwide.
Micro abstract: The efﬁcacy of the FOLFOXIRI plus bevacizumab regimen for patients with
metastatic colorectal cancer has been proven in a recent phase III study. However, there is no
report of the FOLFOXIRI plus bevacizumab regimen in Japanese patients, and recommended
doses of this regimen for Japanese patients have not been determined. The present study.05.003
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H. Satake et al.76demonstrates that the recommended doses of FOLFOXIRI plus bevacizumab for Japanese
patients are the same as the standard doses used worldwide.
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For metastatic colorectal cancer, a cytotoxic doublet combi-
nation of ﬂuorouracil (plus leucovorin) and either irinotecan
[FOLFIRI] or oxaliplatin [FOLFOX] with a targeted agent is
generally proposed as initial chemotherapy, and should be
regarded as the preferred treatment. Recently, however, a
triple-drug combination of irinotecan (CPT-11), oxaliplatin
(L-OHP), ﬂuorouracil (5-FU), and leucovorin (LV) [FOLFOXIRI]
showed a superior response rate, progression-free survival,
and overall survival compared with FOLFIRI [1]. Furthermore,
FOLFOXIRI plus bevacizumab showed a statically signiﬁcant
improvement in response rate and survival compared with
FOLFIRI plus bevacizumab [2]. On the basis of these promising
results, the National Comprehensive Cancer Network clinical
practice guidelines, European Society for Medical Oncology
clinical practice guidelines [3] and Japanese Society for
Cancer of the Colon and Rectum guidelines all now consider
the FOLFOXIRI regimen to be the standard initial treatment
regimen for patients with metastatic colorectal cancer [4].
To date, however, only one report of FOLFOXIRI for Japanese
patients with metastatic colorectal cancer has been pub-
lished, in which the recommended doses were unfortunately
lower than the global standard [5]. Furthermore, there has
been no report of the FOLFOXIRI plus bevacizumab regimen
in Japanese patients. The recommended doses of FOLFOXIRI
plus bevacizumab for Japanese patients with metastatic
colorectal cancer are therefore unknown.
The aim of this study was to determine the recommended
doses (RDs) for phase II studies of FOLFOXIRI plus bevacizu-
mab for Japanese patients with metastatic colorectal
cancer. Secondary endpoints were toxicity and efﬁcacy.2. Patients and methods
2.1. Eligibility criteria
Eligibility criteria were age more than 20 years; histologically
proven colorectal adenocarcinoma with metastatic disease;
Eastern Cooperative Oncology Group (ECOG) performance status
(PS) o2; adequate organ function, as deﬁned by hemoglobin
Z10 g/dl, absolute neutrophil count Z2 109/l, platelets
count Z100 109/l, total bilirubin r1.5 mg/dl, serum transa-
minases r100 U/l and creatinine clearance Z60 mL/min.
Exclusion criteria were evidence of prior chemotherapy with
irinotecan or oxaliplatin; prior myocardial infarction within
three months; history of unstable angina pectoris or intestinal
pneumonia or ﬁbroid lung or severe emphysema; concurrent
active malignancy; uncontrolled infection; severe mental dis-
order; severe peripheral neuropathy; unresolved bowel obstruc-
tion or partial bowel obstruction; pregnancy or lactation and
UDP-glucuronosyltransferase (UGT) 1A1n6/n6, n28/n28 and n6/
n28 genotypes. Homozygosity for UGT1A1n28 or UGT1A1n6 andheterozygosity for both UGT1A1n6 and UGT1A1n28 are asso-
ciated with severe irinotecan-related neutropenia in Japanese
patients [6,7]. All patients were required to provide written
informed consent before entering the study, which was
approved by the Institutional Review Board of Kobe City Medical
Center General Hospital.2.2. Study design and treatment
Protocol treatment was deﬁned as chemotherapy consisting
of L-OHP, CPT-11, LV, 5-FU, plus bevacizumab. Treatment
consisted of a 1-hour intravenous (i.v.) administration of CPT-
11, immediately followed by 2-h concomitant infusion of L-
OHP 85 mg/m2 and LV 200 mg/m2, immediately followed by
48-h continuous i.v. administration of 5-FU 3200 mg/m2. This
regimen was repeated every 2 weeks. In case where both
oxaliplatin and irinotecan could not be administered due to
toxicity or patient refusal, treatment was shifted to the
maintenance phase. Maintenance treatment consisted of
ﬂuorouracil plus leucovorin or capecitabine plus bevacizumab
until disease progression, unacceptable toxic effects, or
withdrawal of consent. Maintenance phase capecitabine plus
bevacizumab treatment consisted of capecitabine (1000 mg/
m2 orally twice a day on days 1–14) with bevacizumab
(7.5 mg/kg intravenously on day 1) given every 3 weeks.
The study was designed to determine the recommended
dose (RD) of chemotherapy. Six patients were treated at dose
level 1 (L-OHP 85 mg/m2, CPT-11 165 mg/m2, LV 200 mg/m2,
5-FU 3200 mg/m2 infused as a 48-h continuous infusion and
bevacizumab 5 mg/kg). If three or more of the six patients
experienced a dose-limiting toxicity (DLT), six additional
patients were accrued at the next lower dose level (L-OHP
85 mg/m2, CPT-11 150 mg/m2, LV 200 mg/m2, 5-FU 3200 mg/
m2 infused as a 48-h continuous infusion and bevacizumab
5 mg/kg). The MTD was deﬁned as the dose at which three or
more of the six patients experienced a DLT. After the MTD
was determined, six more patients were treated at the next
lower dose level to determined the RD. If two or fewer of the
six patients in dose level 1 experienced a DLT, the RD was
determined to be level 1 (L-OHP 85 mg/m2, CPT-11 165 mg/
m2, LV 200 mg/m2, 5-FU 3200 mg/m2 infused as a 48-h
continuous infusion and bevacizumab 5 mg/kg).
The dose was modiﬁed for each patient based on hematologic
or non-hematologic toxicity. DLT was deﬁned as any of the
following adverse events occurring in the ﬁrst cycle: (i) grade
4 neutropenia lasting 44 days; (ii) grade 4 thrombocytopenia
(o0.25 109/l); (iii) febrile neutropenia; (iv) grade 3 or 4 non-
hematological toxic effects; (v) discontinuation of treatment
due to an adverse event; or (vi) treatment-related death.
Treatment was administered biweekly until evidence of progres-
sion, unacceptable toxicity, or patient refusal. Treatment was
delayed if, on the planned day of treatment, neutrophils were
less than 1500/mm3, platelets were less than 75,000/mm3, total




Sex Male 2 (33)
Female 4 (67)
ECOG PS 0 5 (83)
1 1 (17)
Primary tumor location Right hemicolon 2 (33)
Left hemicolon 0 (0)
Rectum 4 (67)
Surgery for primary tumor Yes 5 (83)
No 1 (17)
Previous adjuvant chemotherapy Yes 0 (0)
No 6 (100)
Metastases Synchronous 6 (100)
Metachronous 0 (0)
No. of metastases Single 4 (67)
Multiple 2 (33)
Liver-only metastases Yes 2 (33)
No 4 (67)
Peritoneal metastasis Yes 3 (50)
No 3 (50)
Baseline LDH Normal 4 (67)
Above upper normal limit 2 (33)
Baseline CEA Normal 0 (0)
410 ng/ml 6 (100)
KRAS exon2 Wild type 2 (33)
Mutation type 4 (67)
UGT1A1 WT 3 (50)
*6 single hetero 2 (33)
*28 single hetero 1 (17)
ECOG, Eastern Cooperative Oncology Group; PS, performance status; and WT, wild type.
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stomatitis, or peripheral sensory neurotoxicity higher than grade
1 was present. In the event of peripheral sensory neurotoxicity
Z grade 2 (NCI-CTC), L-OHP was interrupted. In the event of
grade 4 non-hematologic toxicities, treatment was deﬁnitively
interrupted. To prevent chemotherapy-induced nausea and
vomiting (CINV), fosaprepitan, a selective antagonist of the
neurokinin (NK) 1 neurotransmitter receptor 150 mg i.v., palo-
nosetron, a second-generation 5-hydroxytryptamine 3 (5-HT(3))-
receptor antagonist 0.25 mg i.v., and dexamethasone 9.9 mg i.v.
were administered before chemotherapy. Atropine 0.25 mg i.v.
was given in the event of cholinergic syndrome and then given
prophylactically in subsequent cycles. Prophylactic use of
granulocyte colony-stimulating factor (G-CSF) was not allowed.
2.3. Study assessment
Pretreatment evaluation included a medical history; physical
examination; complete blood cell count and serum chemistry
tests; colonoscopy; and chest, abdominal and pelvic CT scans.
During therapy, a complete blood cell and platelet count was
performed weekly. Clinical examination and biochemical tests
were required before and during each cycle. All adverse
events experienced during the study were recorded and
graded according to the National Cancer Institute CommonTerminology Criteria for Adverse Events (CTCAE version 4.0).
The presence of measurable lesions was not required in this
study, but tumor assessments were performed at least every
two months. Response, as determined by the investigators,
was recorded according to RECIST criteria v1.1.2.4. Endpoints
The primary endpoint in this study was the MTD and RD of this
regimen. Secondary endpoints included response rate (RR),
progression-free survival (PFS), overall survival (OS), comple-
tion rate of protocol treatment with 12 cycles, relative dose
intensity and safety. Dose intensity was calculated as the ratio
of the actual to planned dose intensity in milligrams per
square meter per week. The survival curve was estimated
using the Kaplan–Meier method. Safety and efﬁcacy analyses
were both conducted on an intention-to-treat (ITT) popula-
tion, deﬁned as all patients enrolled in the study who received
at least one dose of chemotherapy. The PFS was deﬁned as the
time from the date of the ﬁrst administration of induction
chemotherapy to the ﬁrst documentation of disease progres-
sion, subsequent therapy, or death. OS was determined from
the date of the ﬁrst administration of induction chemotherapy
to the date of death or last conﬁrmation of survival. Statistical
H. Satake et al.78data were obtained using the SPSS software package (SPSS
22.0 Inc., Chicago, IL).
This trial was registered with University Hospital Medical
Information Network (No. UMIN000012991).
3. Results
3.1. Patient characteristics
From March 2014 to December 2014, six patients were
enrolled. Characteristics of the enrolled patients are listed
in Table 1. All patients were chemo-naïve, and half had
peritoneal metastasis. All six patients had histologically
proven adenocarcinoma. Among the six patients, all patients
were treated at the RD (level 1: L-OHP 85 mg/m2, CPT-11
165 mg/m2, LV 200 mg/m2, 5-FU 3200 mg/m2 infused as a 48-
h continuous infusion and bevacizumab 5 mg/kg). In thisTable 2 Maximum toxicity per patient (n=6).
Adverse event NCI CTC grade
Hematologic 1 2 3 4 All (%) 3/4 (%)
Leukopenia 0 1 3 0 67 50
Neutropenia 0 0 2 2 67 67
Anemia 4 1 0 0 83 0
Thrombocytopenia 3 0 0 0 50 0
Febrile neutropenia – – 0 0 0 0
Non-hematologic
Alopecia 1 0 0 0 17 0
Diarrhea 3 1 0 0 67 0
Epistaxis 1 0 0 0 17 0
Fatigue 2 0 0 0 33 0
Fever 1 0 0 0 17 0
Headache 1 0 0 0 17 0
Hiccups 1 0 0 0 17 0
Hoarseness 1 0 0 0 17 0
Hypertension 0 1 0 0 17 0
Hypomagnesemia 2 0 0 0 33 0
Leucoencephalopathy 0 1 0 0 17 0
Nausea 2 0 0 0 33 0
Peripheral sensory neuropathy 6 0 0 0 100 0
Stomatitis 2 0 0 0 33 0
Tinnitus 1 0 0 0 17 0
NCI CTC, National Cancer Institute Common Toxicity Criteria.
Table 3 Dose intensity during the ﬁrst four courses of treatm
Oxaliplatin Ir
Mean (range) M
Target dose, mg/m2 (mg/kg) 340 6
Received dose, mg/m2 (mg/kg) 317.5 (266–340) 6
Target DI, mg/m2/week (mg/kg/week) 42.5 8
Actual DI, mg/m2/week (mg/kg/week) 36.8 (25.9–49.6) 7
% of target DI 86.6% (60.9–117) 8
DI, dose intensity.study, a total of 72 cycles of chemotherapy was adminis-
tered, with a median of 13 cycles per patient (range 5–18).
3.2. Treatment administration and DLT and RD
Six patients were enrolled at dose level 1 (L-OHP 85 mg/m2,
CPT-11 165 mg/m2, LV 200 mg/m2, 5-FU 3200 mg/m2 infused
as a 48-h continuous infusion and bevacizumab 5 mg/kg).
Two of the six patients given level 1 had two cases of DLT
(grade 4 neutropenia lasting 44 days), and hence the RD
was determined to be L-OHP 85 mg/m2, CPT-11 165 mg/m2,
LV 200 mg/m2, 5-FU 3200 mg/m2 infused as a 48-h contin-
uous infusion and bevacizumab 5 mg/kg for phase II studies.
3.3. Toxicity
Toxicity was assessable in all patients until the completion
of 4 cycles. The worst toxicity through the treatment period
is listed in Table 2. Grade 3 or more neutropenia and febrile
neutropenia occurred in 67% and 0% of patients, respec-
tively. Two patients suffered from Grade 4 neutropenia,
however, they recovered without the use of G-CSF within
7 days. Finally, no patient used G-CSF, and no treatment-
related death was observed.
One patient developed grade 2 leucoencephalopathy. This
patient experienced mild headache and mild lethargy after the
fourth cycle of protocol treatment. The physical examination
was essentially normal except for high blood pressure (167/
90 mmHg). T2-weighted magnetic resonance imaging (MRI) of
the brain showed hyperintense areas at the left parietal
subcortical lobe. The patient made a rapid recovery with the
transient cessation of chemotherapy. The blood pressure also
returned to normal after treatment with an antihypertensive
agent. Bevacizumab was discontinued and oxaliplatin, irinote-
can, ﬂuorouracil were continued without the recurrence of
leucoencephalopathy. Follow-up MRI 24 weeks later showed
complete resolution of the leucoencephalopathy.
3.4. Dose intensity
Dose intensity during the ﬁrst four courses of treatment is
shown in Table 3. The median percentage of dose intensity
delivered was 86.6% for oxaliplatin, 86.7% for irinotecan,
90.4% for ﬂuorouracil and 93.2% for bevacizumab. The
average percentage of relative dose intensity (RDI) during
the ﬁrst four course of treatment was 89.2%.ent (n=6).
inotecan Fluorouracil Bevacizumab
ean (range) Mean (range) Mean (range)
60 12800 (20)
17 (526–660) 12432 (10592–12800) (20 (20))
2.5 1600 (2.5)
1.6 (50.2–96.3) 1446 (974–1867) (2.3 (1.5–2.9))
6.7% (60.9–117) 90.4% (60.9–117) 93.2% (60.9–117)
Table 4 Response rate to treatment (n=6).
Variable n % (95% CI)
Overall response 4 66.7 (30.0–90.3)
Complete response 0 0
Partial response 4 66.7 (30.0–90.3)
Stable disease 2 33.3 (9.7–70.0)
Progressive disease 0 0
CI, conﬁdence interval.
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oxaliplatin administration due to peripheral neuropathy at
mean of 9.5 cycles (range 8–13). Furthermore, four patients
have stopped irinotecan administration due to fatigue or at the
investigator's discretion at a mean of 10 cycles (range 8–12).
As mentioned above, one patient stopped bevacizumab
administration due to bevacizumab-induced leucoencepha-
lopathy. However, the other ﬁve were able to receive
bevacizumab administration from the induction phase to
maintenance phase without reduction.
3.5. Efﬁcacy and survival
Response was assessable in all six patients. Response results are
summarized in Table 4. Four of the six patients had partial
response (PR), yielding a response rate of 66.7% (95% conﬁden-
tial interval: 30.0–90.3 %). The other two patients appeared to
have tumor shrinkage, albeit that the shrinkage rate was within
the stable disease (SD) rage according to the RECIST criteria.
With a median follow-up period of 9.3 months (range 2.2–
11.3), all patients remain alive. Two have been shifted to
second-line chemotherapy due to disease progression.
4. Discussion
This is the ﬁrst report of the feasibility and activity of
FOLFIXIRI plus bevacizumab in Japanese patients with
advanced colorectal cancer. The doses of irinotecan in the
FOLFIRI regimen used in Western countries are 180 mg/m2
repeated every two weeks [8]. In Japanese patients, how-
ever, irinotecan is routinely used at a dose of 150 mg/m2 in
the FOLFIRI regimen. This dose has been approved for
irinotecan monotherapy every 2 weeks by the Japanese
Ministry of Health, Labor and Welfare. FOLFOXIRI plus
bevacizumab is recommended as a ﬁrst line chemotherapy
for patients with metastatic colorectal cancer in Japan.
Irinotecan in Japan is given biweekly at 150 mg/m2, whereas
the global standard dose of irinotecan as part of the
FOLFOXIRI regimen is 165 mg/m2 by biweekly administration.
No toxicity or safety data about the standard doses of the
FOLFOXIRI plus bevacizumab regimen for advanced colorectal
cancer patients in Japan are available. We therefore con-
ducted this study to evaluate the safety of the FOLFOXIRI
plus bevacizumab regimen for metastatic colorectal cancer
patients in Japan. The RD of FOLFOXIRI plus bevacizumab in
Japanese patients was determined to be L-OHP 85 mg/m2,
CPT-11 165 mg/mg/m2, LV 200 mg/m2, 5-FU 3200 mg/m2
infused as a 48-h continuous infusion and bevacizumab
5 mg/kg, which is consistent with the global standard.Irinotecan is activated by hydrolysis to SN-38, a potent
topoisomerase I inhibitor [9] which is primarily inactivated
through biotransformation into SN-38 glucuronide (SN-38G)
by UGT1A1 [10]. Polymorphisms of the UGT1A1 gene, such as
n6 and UGT1A1n28, can cause severe neutropenia and
diarrhea in patients who receive irinotecan [7,11]. Homo-
zygosity of UGT1A1n28 is associated with less efﬁcient
glucuronidation of SN-38, the active metabolite of irinote-
can, resulting in increased plasma SN-38 concentrations. The
UGT1A1n28 genotype is associated with irinotecan-induced
hematologic toxicity, diarrhea, or both [12]. UGT1A1n6 is
also associated with severe irinotecan-related toxicity.
Furthermore, the area under the time versus concentration
curve ratios (SN-38 glucuronide/ SN-38) seen in patients
homozygous for UGT1A1n28 and n6 are almost equal [6]. In
Asians, a speciﬁc mutation, UGT1A1n6 [13], has been proved
to reduce the catalytic activity of UGT1A1 [14,15]. Homo-
zygosity for UGT1A1n28 (n28/n28) or UGT1A1n6 (n6/n6) and
heterozygosity for both UGT1A1n28 and n6 (n28/n6) are
associated with severe irinotecan-related neutropenia in
Japanese patients [6,7]. The TRIBE trial, a cornerstone phase
III trial of FOLFOXIRI plus bevacizumab for metastatic color-
ectal cancer, reported that the rate of FN was 8.8% and grade
3 or more neutropenia was 50.0% [2]. In contrast, our present
study showed an FN rate of 0%, and grade 3 or more
neutropenia of 67%. As mentioned above, UGT1A1 plays a
role in the adverse events of bone marrow suppression, and
exclusion of patients with UGT1A1n28/n28, n6/n6 or n28/n6
might be one reason why no patient in our study experienced
FN case as an adverse event.
In this study, one patient experienced grade 2 leucoencepha-
lopathy. Leucoencephalopathy post chemotherapy is a very rare
complication that affects the central nervous system. Posterior
reversible leucoencephalopathy syndrome (PRLS) is the most
commonly reported; it is characterized by an impairment of the
white matter of the posterior cerebral hemispheres [16]. In
some cases, this syndrome can affect the anterior hemisphere,
gray matter, brainstem, subcortical substance and basal ganglia
[17–19]. Bevacizumab-based combination chemotherapy is asso-
ciated with the risk of grade 3 hypertension in up to 16 percent
of patients, possibly secondary to vasospasm [20]. Severe
hypertensive encephalopathy leads to RPLS and vasogenic
edema, induced by endothelial dysfunction and a disrupted
blood brain barrier [16,21,22]. Headache is the most common
sign found in clinical settings, and disorientation in time and
space have also been reported [23,24]. Diagnosis is primarily by
MRI, and shows signs of abnormality affecting the white matter
as hyperintense lesions on T2 [16,17,19]. This syndrome usually
resolves after discontinuation of the agent responsible [16,19].
In our case, clinical ﬁndings were typical, but the MRI ﬁndings
were unilateral, which is atypical. Nevertheless, the symptoms
rapidly recovered after the transient cessation of chemotherapy
and medication with an antihypertensive drug. It is difﬁcult to
decide on the drug responsible for this syndrome but the
symptoms and MRI ﬁndings both recovered with the disconti-
nuation of bevacizumab.
A limitation of the present study related to study design
should be discussed. We initially planned a de-escalation design
for this study. The dose of irinotecan did not reach the MTD.
Therefore, the question remains whether the doses of irinote-
can could have been escalated higher in Japanese patients
without the UGT1A1n28/n28, n6/n6 or n28/n6 genotypes.
H. Satake et al.805. Conclusion
In conclusion, this phase I study demonstrates that the RDs
of FOLFOXIRI plus bevacizumab for Japanese patients are
the same as those used worldwide. Toxic effects at these
doses are manageable based on this protocol setting. A
phase II study of FOLFOXIRI plus bevacizumab as ﬁrst-line
therapy in patients with metastatic colorectal cancer is now
ongoing as the QUATTRO trial (No. UMIN000013797).
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